Literature DB >> 27922042

Neuroendocrine tumours in 2016: Defining rules for increasingly personalized treatments.

Massimo Falconi1, Stefano Partelli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27922042     DOI： 10.1038/nrclinonc.2016.197

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Authors:  Laura H Tang; Brian R Untch; Diane L Reidy; Eileen O'Reilly; Deepti Dhall; Lily Jih; Olca Basturk; Peter J Allen; David S Klimstra
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

2.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

3.  Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms.

Authors:  Mohid S Khan; Amy A Kirkwood; Theodora Tsigani; Helen Lowe; Robert Goldstein; John A Hartley; Martyn E Caplin; Tim Meyer
Journal:  Clin Cancer Res       Date:  2015-07-21       Impact factor: 12.531

4.  Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.

Authors:  L Bodei; M Kidd; I M Modlin; S Severi; I Drozdov; S Nicolini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

5.  A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.

Authors:  Laura H Tang; Olca Basturk; Jillian J Sue; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2016-09       Impact factor: 6.394

6.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Authors:  James C Yao; Nicola Fazio; Simron Singh; Roberto Buzzoni; Carlo Carnaghi; Edward Wolin; Jiri Tomasek; Markus Raderer; Harald Lahner; Maurizio Voi; Lida Bubuteishvili Pacaud; Nicolas Rouyrre; Carolin Sachs; Juan W Valle; Gianfranco Delle Fave; Eric Van Cutsem; Margot Tesselaar; Yasuhiro Shimada; Do-Youn Oh; Jonathan Strosberg; Matthew H Kulke; Marianne E Pavel
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321
  6 in total
  1 in total

1.  EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.

Authors:  James Saller; Shabnam Seydafkan; Mohammad Shahid; Manoj Gadara; Mauro Cives; Steven A Eschrich; David Boulware; Jonathan R Strosberg; Nasir Aejaz; Domenico Coppola
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.